/C O R R E C T I O N -- Genzyme Corporation/

In the news release, Genzyme Completes Tender Offer to Acquire Bioenvision, Inc., issued earlier today by Genzyme Corporation over PR Newswire, we are advised by Genzyme that the company will purchase approximately 22 percent of outstanding shares of Bioenvision common stock on an as-converted basis, including the 100 percent of outstanding shares of preferred stock that have already been tendered.  Further, as of today at 12:01 a.m., a total of approximately 8,706,644 shares of Bioenvision common stock and 2,250,000 shares of Bioenvision preferred stock had been tendered and not withdrawn. 

DATASOURCE: Genzyme Corporation



Web site:  http://www.genzyme.com/ 



Company News On-Call:  http://www.prnewswire.com/comp/113803.html 

Copyright